Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

oduct liability, supply, competition and other risks).

-more-

(Financial Table Attached)

ENTREMED, INC.

SUMMARY OF OPERATING RESULTS

Three Months Ended

September 30,

2008 2007

Total revenues $3,501,307 $3,520,259

Research and development 4,957,067 5,109,257

General and administrative 1,551,900 1,706,451

Acquired in-process research and development 0 0

Net Loss (3,397,877) (3,035,346)

Net Loss per share (basic and diluted)

attributable to common shareholders $(0.04) $(0.04)

Weighted average number of shares

outstanding (basic and diluted) 87,728,644 84,223,912

Nine Months Ended

September 30,

2008 2007

Total revenues $3,501,307 $3,520,259

Research and development 16,629,127 18,089,240

General and administrative 5,274,585 5,407,588

Acquired in-process research and development 2,000,000 0

Net Loss (21,314,476) (18,643,625)

Net Loss per share (basic)

attributable to common shareholders $(0.26) $(0.23)

Weighted average number of shares

outstanding (basic) 86,060,438 84,015,999

Ca
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed across ... in the process of being consolidated in a Kansas federal ... Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 in ... Management of the Syngenta GMO corn multidistrict litigation (MDL) has ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Inverness Medical,Innovations, Inc. (Amex: IMA ) ... dated January 31, 2008 and entitled "Inverness Medical,Innovations ... and Medical Device Conference on February 5, 2008." ... Company,s presentation. The,correct time of the presentation is ...
... Calif., Feb. 1 Edwards Lifesciences,Corporation (NYSE: ... technologies to,treat advanced cardiovascular disease, is scheduled to ... Medical Device,Conference at the Grand Hyatt Hotel in ... M. Abate, Edwards Lifesciences, corporate vice president, chief,financial ...
... Inc.,(Nasdaq: VRUS ) management will be presenting at ... February 11 - 13, 2008 at the,Waldorf-Astoria Hotel in ... provide an overview of the company on Monday,February 11, ... Salon. In,addition, Dr. Michelle Berrey, Pharmasset,s Chief Medical Officer, ...
Cached Biology Technology:Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th 2
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
(Date:1/22/2015)... NEW YORK , Jan. 22, 2015   EyeLock, Inc. ... announced it has appointed Steve Gerber to the ... Gerber will be responsible for leading development of mobile platforms ... 25 years of success and innovation in the semiconductor industry ...
(Date:12/22/2014)... Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" or ... mobile commerce market, announces it has retained famous pickpocket, entertainer ... International CES debut of the Wocket™ biometric smart wallet.  ... NXT-ID booth January 6th and 7 th , 2015, demonstrating ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... MD FASEB MARC (Maximizing Access to Research Careers) ... Society for the Study of Reproduction (SSR) Annual Meeting ... These awards are meant to promote the entry of ... of the basic science community and to encourage the ...
... systems work together to paralyze skeletal muscles during rapid eye ... 11 issue of The Journal of Neuroscience . The ... including narcolepsy, tooth grinding, and REM sleep behavior disorder. ... recalled dreams occur your eyes continue to move but ...
... has been awarded a grant expected to total more ... (NIH) National Institute of Allergy and Infectious Diseases (NIAID). ... vaccine against HIV and the disease it causes, AIDS. ... vaccine is urgently needed to slow and eventually eliminate ...
Cached Biology News:Study identifies how muscles are paralyzed during sleep 2Scripps Research Institute wins $77 million to develop AIDS vaccine center 2Scripps Research Institute wins $77 million to develop AIDS vaccine center 3
... The BD FACSAria cell sorter sets a ... Based on a revolutionary new design ... high-speed sorting and multicolor analysis. The BD ... that incorporates a fixed-alignment cuvette flow cell. ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
Biology Products: